MedTrace Logo

EUS-guided CTCs + Multi-omics: Predicting Pancreatic Cancer Recurrence and Metastases

NCT07448376 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2026-03-04

No results posted yet for this study

Summary

The investigators conduct a single-center, prospective, observational study to explore the value of EUS-guided portal vein circulating tumor cells (PV-CTCs) and their subtypes combined with multi-omics tests in the early warning of recurrence and metastasis of resectable pancreatic cancer(RPC) and borderline resectable pancreatic cancer (BRPC).

Conditions

Interventions

DIAGNOSTIC_TEST

CTC

Obtaining portal vein blood and peripheral blood from patients, extracting circulating tumor cells (CTCs) therein, and performing CTC sorting, thereby assisting clinical evaluation of the applicability of neoadjuvant therapy and prognostic assessment for patients with potentially resectable pancreatic cancer.

Sponsors & Collaborators

  • Huazhong University of Science and Technology

    lead OTHER

Principal Investigators

  • Bin Cheng · Tongji Hospital

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-01
Primary Completion
2027-12-30
Completion
2027-12-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07448376 on ClinicalTrials.gov